In order to prevent errors in administering tixagevimab/cilgavimab (EVUSHELD), an alert will display when you attempt to order or administer tixagevimab/cilgavimab (EVUSHELD) to a patient that weighs 40 kg or less. You will not be allowed to place the order or proceed with administration.

Tixagevimab/cilgavimab is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19 and is strictly regulated by weight.